The FDA on November 25, 2019 granted accelerated approval to OXBRYTA® for adults and pediatric patients 12 years of age and older with Sickle Cell disease. OXBRYTA® is a product of Global Blood Therapeutics.
Bottom Ad
Advertisement
Subscribe
Top Ad
Advertisement